the eucapnic hyperventilation of cold dry air. The precise mechanism of this effect, including Background -Leukotrienes have been imthe role of biochemically active mediators, is plicated in the mediation of airway obunknown. The cysteinyl leukotrienes (LTC 4 , struction induced by hyperventilation of LTD 4 , and LTE 4 ) are potent mediators of cold dry air in asthmatic subjects. The bronchoconstriction that possess proinflameffect of a novel inhibitor of 5-lipoxygenase matory properties. They have been implicated activating protein, BAYx 1005, on the in the pathobiology of asthma, including bronchospastic response to cold dry air asthma induced by cold dry air.
hypothesis that leukotrienes mediate part study. All subjects gave their written informed of the bronchoconstriction induced by Presented (in part) at the consent to participate in the protocol which was annual meeting of the hyperventilation of cold dry air.
approved by the Committee on Clinical In- double blind, crossover design, followed three Bayer AG) and thromboxane B 2 using standard methodology. hours later by cold air challenge. The FEV 1 was measured every 30 minutes after BAYx Plasma levels of BAYx 1005 were measured in unstimulated samples using a standard 1005 dosing until the start of the cold air challenge and every 15 minutes for one hour HPLC assay. All the eicosanoid data from one subject (no. 15) were excluded because LTB 4 after completion of the cold air challenge. An average of nine days (range 7-21) later the was not detected in stimulated blood three hours after ingestion of BAYx 1005; very low subjects returned, crossed over to the alternative treatment, and underwent the identical levels of TxB 2 were detected in that specimen as well. challenge protocol. The techniques for performing the cold air challenges have been described previously.
2 Challenges for individual    subjects were performed at the same time of All cold air challenge data analyses were perday. The amount of cold air minute ventilation formed on log 10 transformed data. Cold air needed to produce a 10% or 20% decrease in challenge data are reported as geometric means FEV 1 was determined by linear interpolation (standard error of the geometric mean) and from the log 10 dose-response curves. The time analysed with a standard crossover ANOVA. for the FEV 1 to return to within 5% of baseline An analysis of covariance (ANCOVA) using was obtained by linear interpolation from the the prechallenge FEV 1 (0-3 hours after drug FEV 1 data obtained after cold air challenge. ingestion) as a covariant was performed to The ability of BAYx 1005 to inhibit eicos-adjust for the effect of prechallenge bronchoanoid production was estimated via ex vivo dilation. Continuous variables were reported measurement of LTB 4 and thromboxane B 2 as means with a range or 95% confidence (TxB 2 ) production in whole blood stimulated interval. A paired t test was used to detect with calcium ionophore A23187. Blood was differences between groups. No sequence or drawn immediately before ingestion of BAYx period effects were found so all data were 1005 and three hours later (just prior to the analysed together. cold air challenge). Aliquots were stimulated with calcium ionophore A21387 (50 M) and incubated for 30 minutes. Serum was collected Results
Eighteen men of mean age 27 years (range and stored at −80 o C until assay for LTB 4 (assay courtesy of Dr R Mü ller-Peddinghaus, 19-41) were enrolled and 16 completed the group.bmj.com on July 8, 2017 -Published by http://thorax.bmj.com/ Downloaded from study. Two were excluded because of illnesses these effects have not been well defined. Our previous studies have shown that treatment occurring before completion of the double blind phase; both subjects had received with inhibitors of 5-lipoxygenase or cysteinyl leukotriene receptor antagonists blunts the placebo. The mean baseline FEV 1 was 3.76 l (range 2.60-5.21) or 86% predicted (range bronchospastic response to the eucapnic hyperventilation of cold dry air. 2 6 The current data 60-114%). The mean (SE) baseline PD 20 V  was 51.7 (1.07) l (range 33.6-87.0).
show blunting of cold air-induced bronchospasm by an agent that inhibits leukotrienes by The mean plasma level of BAYx 1005 three hours after ingestion was 9.7 g/ml (range 3.0-a third mechanism of action -inhibition of FLAP. 9 These results provide further evidence 21.1). BAYx 1005 was not detected in the plasma of any subject before dosing or three that the salutary effects of "antileukotriene" drugs on cold air hyperventilation relate to their hours after placebo ingestion. There was no significant difference in FEV 1 before drug ad-effects on leukotrienes rather than to some other non-specific bronchodilating effects of ministration on the placebo challenge day compared with the BAYx 1005 challenge day those agents. While we did observe some bronchodilation, our analysis shows that the (3.55 l (2.63-4.48) and 3.57 l (2.55-4.54), respectively. The FEV 1 increased 0.31 l three effect of BAYx 1005 was independent of the small degree of prechallenge bronchodilation. hours after BAYx 1005 ingestion compared with 0.15 l three hours after placebo ingestion, It is interesting to compare the degree of protection afforded by BAYx 1005 against cold air a difference of 0.16 l (95% CI, 0.06 to 0.26) (p<0.009).
challenge with that of other agents active against leukotriene formation or action. BAYx The cold air challenge data of individual subjects are shown in fig 1. The PD 10 V  in-1005 increased the amount of cold dry air hyperventilation needed to produce a 10% and creased by 34% (95% CI 11 to 63) after treatment with BAYx 1005 compared with placebo 20% decrease in FEV 1 (PD 10 and PD 20 ) by 34% and 19%, respectively. Its effects approximated (37.6 (1.12) versus 28.0 (1.13) l/min, p<0.006), while the PD 20 V  increased by 19% that of the leukotriene receptor antagonist LY171883 which produced a 22% increase in (95% CI 8 to 31) after treatment with BAYx 1005 compared with placebo (57.3 (1.10) ver-PD 20 V  after two weeks of treatment at a dose of 600 mg twice daily. 6 However, the degree sus 48.1 (1.10) l/min, p<0.002). This increase in PD 20 V  after BAYx 1005 was significantly of inhibition produced was less than a single 800 mg dose of the 5-LO inhibitor zileuton, different from that after placebo, despite prechallenge bronchodilation (p<0.04, which increased the PD 10 V  by 45%. 2 The reasons for the lesser magnitude of protection ANCOVA). Since cold dry air hyperventilation was increased until each subject achieved at with BAYx 1005 are unclear but may include poor tissue penetration, differences in protein least a 20% fall in FEV 1 , subjects achieved nearly the same maximal decline in FEV 1 after binding characteristics of BAYx 1005, or intrinsic differences in drug potency. the challenge -74% of baseline after BAYx 1005 compared with 73% of baseline after Considering the physiological effects of BAYx 1005, we believe that the small degree placebo. However, when subjects were treated with BAYx 1005 the FEV 1 returned toward of ex vivo inhibition of leukotriene synthesis observed was due in part to the experimental baseline more rapidly than with placebo. The FEV 1 reached 95% of baseline 22 minutes conditions under which ionophore stimulation occurred. Our studies were carried out at pH (range 8-60) after cold air challenge on the day of treatment with BAYx 1005 compared 7.4 with 50 M ionophore. Studies carried out two hours after a single 500 mg dose of BAYx with 36 minutes (range 15-60) after cold air challenge on the day of treatment with placebo; 1005, at a time drug levels were similar to those seen in our study but at pH 7 using an hence the FEV 1 was within 5% of the prechallenge FEV 1 14 minutes (95% CI 6 to 22) ionophore concentration of 5 M, showed 81% inhibition of LTB 4 production compared with faster after BAYx 1005 treatment than after placebo (p=0.002).
33% inhibition of ionophore-stimulated LTB 4 production at pH 7.4 using an ionophore conBAYx 1005 inhibited the change in ex vivo calcium ionophore-stimulated LTB 4 pro-centration of 30 M (data on file, Bayer AG).
In summary, using a FLAP inhibitor our data duction compared with placebo (p<0.02). Treatment with BAYx 1005 produced a 15.4% provide further confirmation that 5-lipoxygenase products play a part in mediating decrease in whole blood ex vivo calcium ionophore-stimulated LTB 4 production. In con-the airway narrowing that occurs after hyperventilation of cold dry air. Since leukotrienes trast, on the day subjects received placebo there was a 7.1% increase in whole blood ex vivo only appear to play a partial role in mediating this bronchospastic response, the clinical usecalcium ionophore-stimulated LTB 4 production.
fulness of BAYx 1005 may need to be evaluated further in larger studies of spontaneous asthma. No significant adverse events related to BAYx 1005 occurred during the study. 
